Skip to main content

MedRhythms Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

CB Insights today named MedRhythms, a digital therapeutics company building direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury, to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. This year’s Digital Health 150 was unveiled live during CB Insights’ annual Future of Health event.

MedRhythms’ cutting edge, patented digital therapeutics platform uses music to directly target the human motor system to improve walking following neurologic disease and injury. This intervention is based on decades of neuroscience and clinical research in the neuroscience of music and how it can enhance neuroplasticity and improve walking. Sensors connect to the shoe and collect clinical grade data about the patient walking in real-time, and the company’s proprietary algorithms build customized interventions to improve speed and quality of walking of the users.

The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 deals since 2016 and includes startups at various investment stages of development, from early-stage to well-funded unicorns. Companies this year include startups working on data integration & analytics, hybrid virtual / in-person care, digital therapeutics, clinical intelligence, and more.

“This year’s Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “Last year's class has seen more than 20 exits, raised an additional $18.6B in aggregate funding, and announced over 250 partnerships since being recognized, and we’re excited to see the future success of this year’s winners.”

“We’re thrilled that CB Insights has recognized our accomplishments this year, including our partnership with Universal Music Group, $27M Series B financing and continued growth of our team,” said Brian Harris, CEO & Founder, MedRhythms. “The growth and momentum we’ve seen this year speaks to the need for next-generation digital therapeutics for patients to help improve walking in those living with neurologic injury and disease. We are honored to be named to the CB Insights Digital Health 150 ranking. This recognition is a testament to our team’s tireless work and commitment to improving the lives of the patients we serve.”

Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from a pool of over 11,000 companies, including applicants and nominees. They were chosen based on several factors, including data submitted by the companies, company business models and momentum in the market, and Mosaic scores, CB Insights’ proprietary algorithm that measures the overall health and growth potential of private companies.

In 2021, MedRhythms launched several clinical studies and expanded its pipeline to include Parkinson’s disease, acute stroke, and a neuroimaging study in multiple sclerosis with Massachusetts General Hospital. The Company also announced a partnership with Universal Music Group (UMG), the world leader in music-based entertainment, that provides MedRhythms with access to UMG’s catalog of the most diverse and culturally rich collection of music ever assembled for the purpose of providing prescription music to patients.

About MedRhythms

MedRhythms is a digital therapeutics company that uses sensors, music and software to build evidence-based neurologic interventions to measure and improve walking. The company is developing a pipeline of digital therapeutics in neurological conditions such as Parkinson’s, acute stroke and multiple sclerosis, including a neuroimaging study with Massachusetts General Hospital. MedRhythms has received FDA Breakthrough Device designation for its lead digital therapeutic to treat chronic stroke walking deficits. The company was founded out of Spaulding Rehabilitation Hospital, one of the leading rehabilitation hospitals in the United States. MedRhythms is headquartered in Portland, Maine. For more information, please visit


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.